GOSSELIES, Wallonia, Belgium--(BUSINESS WIRE)--Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET) (Brussels:ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces today the commercial launch of its BIOCERA-VET® products including BIOCERA-VET® Bone Surgery Ready-to-Use, BIOCERA-VET® Granules and BIOCERA-VET® Osteosarcoma Ready-To-Use in United States of America. With about 89 million dogs, 104 million cats and a pet ownership above 50%1, it is the largest companion animals health market with $4.8 bn revenues estimated in 2021 and an estimated CAGR2 of 10.2% over the next 8 years (2022-2030)3.
The BIOCERA-VET line being available in all USA, TheraVet will initially focus its marketing and commercial efforts on the states of Texas, Florida and Carolinas. These four states were selected as they gather more than 20% of US orthopedic specialists and some of the highest pet ownership rate of the US, as it is ranging from 56 to 59% and as TheraVet has currently its main collaborations with important Key Opinion Leaders in Texas and in the Carolinas.
BIOCERA-VET synthetic bone substitutes including BIOCERA-VET® Bone Surgery RTU (2 references), BIOCERA-VET® Granules (3 references) and BIOCERA-VET® Osteosarcoma RTU (2 references) will be available to the US market through TheraVet’s webshop (www.bioceravet.com). BIOCERA-VET® SMARTGRAFT will be available in US in the coming weeks.
Enrico Bastianelli, Chief Executive Officer of TheraVet, comments: “The commercial launch of BIOCERA-VET® in the USA was one of our main objectives for the year. We are excited to enter the largest companion market with this unique line of products”.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary in Texas.
In close collaboration with an international scientific board, THERAVET® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.
BIOCERA-VET® is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, ready-to-use highly injectable self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone graft
- BIOCERA-VET® GRANULES, an affordable biocompatible calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty
For more information , visit BIOCERA-VET website.
1 U.S. Department of Commerce; Sundale Research Report 2020
2 CAGR: Compound annual growth rate
3 https://www.grandviewresearch.com/industry-analysis/us-companion-animal-health-market; https://www.businesswire.com/news/home/20220601005747/en/United-States-Companion-Animal-Health-Market-Report-2022-Market-to-Reach-11.39-Bn-by-2030---Rising-Number-of-Companion-Ownership---ResearchAndMarkets.com